Detection and evaluation of antibody formation against biologics in psoriasis
Recruiting
- Conditions
- psoriasis1000381610014982
- Registration Number
- NL-OMON35618
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 240
Inclusion Criteria
- Written informed consent
- Patients diagnosed with chronic plaque type psoriasis
- Treatment with a biologic (etanercept, adalimumab, infliximab or efalizumab) for chronic moderate to severe plaque psoriasis started not longer than 52 weeks before.
- Consecutive patients starting treatment with a biologic (etanercept, adalimumab, infliximab or efalizumab) for chronic plaque psoriasis.
Exclusion Criteria
- Previous treatment with the same biologic.
- Patients unable to comply with the requirements of the study
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The serum level of antibodies against the concerning biologic.</p><br>
- Secondary Outcome Measures
Name Time Method <p>The disease severity objectivated by the PASI in patients with antibodies to<br /><br>biologics compared to patients without antibodies to biologics at several<br /><br>timepoints. </p><br>